Strong partnerships are essential for research. Johan Emilsson, CEO of Sprint Biosciences, and Lionel Trésaugues, Director of Structure-Based Drug Design at Sprint Biosciences, were interviewed during a visit to MAX IV about the long-standing collaboration between the company and the research facility.

MAX IV plays an important role in Swedish and international research by providing researchers and companies with access to advanced infrastructure for fields such as structural biology and drug development. For Sprint Bioscience, access to state-of-the-art technology and expertise is a key part of its work to identify and develop new drug candidates.

We are proud to be part of a collaboration that not only strengthens Sweden’s research infrastructure but also contributes to the future of drug development. CEO Johan Emilsson says, among other things, in the interview:

”It’s a luxury to have this expertise and infrastructure right around the corner. We’re very excited about this collaboration, which enables us to push the boundaries of what’s possible while continuing to invest in high-quality research infrastructure in Sweden.”

Together with MAX IV, we continue to explore new opportunities and push the boundaries of what is possible in structure-based drug design.

Read the full article here: Industry Demand Drives the Success of AutoMAX at MAX IV